Cargando…
Therapeutic efficacy and artemisinin resistance in northern Myanmar: evidence from in vivo and molecular marker studies
BACKGROUND: In Myanmar, three types of artemisinin-based combination therapy (ACT) are recommended as first-line treatment of uncomplicated falciparum malaria: artemether–lumefantrine (AL), artesunate–mefloquine (AS + MQ), and dihydroartemisinin–piperaquine (DP). Resistance to both artemisinins and...
Autores principales: | Myint, Moe Kyaw, Rasmussen, Charlotte, Thi, Aung, Bustos, Dorina, Ringwald, Pascal, Lin, Khin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383981/ https://www.ncbi.nlm.nih.gov/pubmed/28388902 http://dx.doi.org/10.1186/s12936-017-1775-2 |
Ejemplares similares
-
Clinical and molecular surveillance of artemisinin resistant falciparum malaria in Myanmar (2009–2013)
por: Nyunt, Myat Htut, et al.
Publicado: (2017) -
Efficacy and Safety of Pyronaridine–Artesunate for the Treatment of Uncomplicated Plasmodium falciparum and Plasmodium vivax Malaria in Myanmar
por: Han, Kay Thwe, et al.
Publicado: (2020) -
Using supply side evidence to inform oral artemisinin monotherapy replacement in Myanmar: a case study
por: Khin, Hnin Su Su, et al.
Publicado: (2016) -
Malaria profiles and challenges in artemisinin resistance containment in Myanmar
por: Nwe, Thet Wai, et al.
Publicado: (2017) -
Oral artemisinin monotherapy removal from the private sector in Eastern Myanmar between 2012 and 2014
por: Khin, Hnin Su Su, et al.
Publicado: (2016)